Skip to main content

Table 4 Comparison of RV functions in the control group vs. thrombolysis group

From: Clinical outcomes of submassive pulmonary embolism thrombolysis—an Indian experience

 

Control group

Thrombolysis group

N (%)

p value

N (%)

p value

Dilated RA/RV

Pre vs. post

20 (45.5%) vs. 20 (45.5%) (n = 44)

1.000

26 (61.9%) vs. 11 (26.2%) (n = 42)

0.001*

Pre vs. day 30

14 (40.0%) vs. 13 (37.1%) (n = 35)

1.000

21 (58.3%) vs. 6 (16.7%) (n = 36)

0.001*

Post vs. day 30

14 (40.0%) vs. 13 (37.1%) (n = 35)

1.000

10 (27.8%) vs. 6 (16.7%) (n = 36)

0.344

RV systolic dysfunction

Pre vs. post

24 (54.5%) vs. 21 (47.7%) (n = 44)

0.629

22 (52.4%) vs. 8 (19.0%) (n = 42)

0.004*

Pre vs. day 30

19 (37.1%) vs. 11 (31.4%) (n = 35)

0.096

19 (52.8%) vs. 3 (8.3%) (n = 36)

0.0001*

Post vs. day 30

19 (54.3%) vs. 11 (31.4%) (n = 35)

0.057

5 (13.9%) vs. 3 (8.3%) (n = 36)

0.727

Tricuspid regurgitation

Pre

Mild

5 (11.4%)

0.064

7 (16.7%)

0.0001*

Moderate

29 (65.9%)

22 (52.4%)

Sever

10 (22.7%)

13 (31.0%)

Post

Mild

15 (34.1%)

32 (76.2%)

Moderate

22 (50.0%)

10 (23.8%)

Sever

7 (15.9%)

0 (0.0%)

Pre

Mild

4 (11.4%)

0.011*

6 (16.7%)

0.0001*

Moderate

22 (62.9%)

20 (55.6%)

Sever

9 (25.7%)

10 (27.8%)

Day 30

Mild

15 (42.9%)

23 (63.9%)

Moderate

15 (42.9%)

13 (36.1%)

Sever

5 (14.3%)

0 (0.0%)

Post

Mild

12 (34.3%)

0.678

26 (72.2%)

0.678

Moderate

18 (51.4%)

10 (27.8%)

Sever

5 (14.3%)

0 (0.0%)

Day 30

Mild

15 (42.9%)

23 (63.9%)

Moderate

15 (42.9%)

13 (36.1%)

Sever

5 (14.3%)

0 (0.0%)

  1. *p value < 0.05, statistically significant
  2. Pre pre-treatment, post post-treatment (within 48 h of treatment)